Unusual Presentations of Metastatic Prostate Carcinoma as Detected by anti-3 F-18 FACBC PET/CT

• Type of Material: Article
• Authors: Rianot Amzat, Emory University; Pooneh Taleghani, Emory University; Bital Savir Baruch, Emory University; Peter Nieh, Emory University; Viraj Master, Emory University; Raghuveer Halkar, Emory University; Melinda Lewis, Emory University; Michelle Faurot, Emory University; Leah M. Bellamy, Emory University; Mark Goodman, Emory University; David Schuster, Emory University
• Language: English
• Date: 2011-09-01
• Publisher: Lippincott, Williams & Wilkins
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2011 by Lippincott Williams & Wilkins.
• Final Published Version (URL): http://dx.doi.org/10.1097/RLU.0b013e318219b47e
• Title of Journal or Parent Work: Clinical Nuclear Medicine
• ISSN: 0363-9762
• Volume: 36
• Issue: 9
• Start Page: 800
• End Page: 802
• Grant/Funding Information: Research sponsored by the NIH (1 R01 CA 129356-01) and the Georgia Cancer Coalition.
• Keywords: Science & Technology; Radiology, Nuclear Medicine & Medical Imaging; ACID; anti-3 F-18 FACBC; Life Sciences & Biomedicine; PET; prostate cancer; CANCER
• Research Categories: Health Sciences, Radiology; Health Sciences, Pathology

Abstract

Prostate carcinoma is the second most common cause of cancer-related mortality in males in the United States. The pattern of metastatic disease of prostate cancer is well recognized, frequently involving sclerotic bone lesions and abdominopelvic lymph nodes. Anti-3 F-18 FACBC acid is a synthetic amino acid analog positron emission tomography radiotracer with reported utility in the detection of prostate carcinoma. We present 2 cases of unusual presentations of prostate carcinoma, one with malignant ascites and omental implants and the other with lytic bone lesions detected with anti-3 F-18 FACBC acid.